Amneal Pharmaceuticals (AMRX) Income from Non-Controlling Interests (2017 - 2026)

Amneal Pharmaceuticals' Income from Non-Controlling Interests history runs 10 years deep, the most recent figure standing at $15.7 million for Q1 2026.

• In Q1 2026, Income from Non-Controlling Interests rose 26.73% year-over-year to $15.7 million; the TTM figure through Mar 2026 stood at $59.2 million (up 30.19% YoY), while the FY2025 annual figure was $55.9 million, up 29.91% from the prior year.
• Income from Non-Controlling Interests was $15.7 million for Q1 2026 at Amneal Pharmaceuticals, up from $14.5 million in the prior quarter.
• In the past five years, Income from Non-Controlling Interests ranged from a high of $17.8 million in Q2 2023 to a low of -$119.3 million in Q2 2022.
• Historically, Income from Non-Controlling Interests has averaged $1.5 million across 5 years, with a median of $10.8 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Income from Non-Controlling Interests plunged 776.0% in 2022, then surged 5034.11% in 2023.
• A 5-year view of Income from Non-Controlling Interests shows it stood at -$1.5 million in 2022, then soared by 447.87% to $5.3 million in 2023, then jumped by 94.89% to $10.3 million in 2024, then soared by 40.22% to $14.5 million in 2025, then grew by 8.6% to $15.7 million in 2026.
• The last three Income from Non-Controlling Interests figures came in at $15.7 million (Q1 2026), $14.5 million (Q4 2025), and $15.8 million (Q3 2025), per Business Quant data.